Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
GlaxoSmithKline
Study ID
NCT06926673
Phase
PHASE2
Status
Completed

Conditions

  • Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dostarlimab — DRUG
    Dostarlimab will be administered
  • Belrestotug. — DRUG
    Belrestotug will be administered
  • Nelistotug — DRUG
    Nelistotug will be administered.

Study Details

This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.

Key Dates

Start date
Dec 23, 2021
Status verified
Jun 2025
Primary completion
May 2, 2024
Completion
May 2, 2024

Study Design

Enrollment
62 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dostarlimab plus Belrestotug
  • Experimental: Dostarlimab plus Belrestotug plus Nelistotug

Primary Outcome Measure

Part 1: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Arm 4) [ Time Frame: Up to approximately 97 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
GSK Investigational SIteNashvilleTennessee37203-

Find similar trials in Nashville, TN

By research site
GSK Investigational SIte· Nashville, TN

Related Studies